IP Verse

Anti Human Interleukin-1 Receptor Accessory Protein (Il1Rap) Antibodies And Uses Thereof - EP3293202

The patent EP3293202 was granted to Cantargia on Feb 7, 2024. The application was originally filed on Mar 5, 2015 under application number EP17185792A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3293202

CANTARGIA
Application Number
EP17185792A
Filing Date
Mar 5, 2015
Status
Patent Maintained As Amended
Jan 5, 2024
Grant Date
Feb 7, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BLUEFIN BIOMEDICINENov 24, 2021DEHNSADMISSIBLE
ICHNOS SCIENCESNov 24, 2021-ADMISSIBLE
ZWICKER SCHNAPPAUF & PARTNERNov 24, 2021ZWICKERADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0213303
DESCRIPTIONEP2213683
DESCRIPTIONUS4235871
DESCRIPTIONUS4816567
DESCRIPTIONUS5851451
DESCRIPTIONUS7960512
DESCRIPTIONWO03059973
DESCRIPTIONWO2005007197
DESCRIPTIONWO2011021014
DESCRIPTIONWO2012098407
OPPOSITIONEP3020730
OPPOSITIONWO2012098407
OPPOSITIONWO2014113433
OPPOSITIONWO9623067
SEARCHWO2012098407

Non-Patent Literature (NPL) Citations (139) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANGOV, Biotechnol. J., (20110000), vol. 6, no. 6, pages 650 - 659-
DESCRIPTION- ARMOUR et al., Eur J Immunol., (19990000), vol. 29, no. 8, pages 2613 - 24-
DESCRIPTION- ARMOUR KL. et al., Eur J Immunol., (19990000), vol. 29, no. 8, pages 2613 - 24-
DESCRIPTION- ASKMYR et al., Blood, (20130000), vol. 121, no. 18, pages 3709 - 13-
DESCRIPTION- BARREYRO et al., Blood, (20120000), vol. 120, no. 6, pages 1290 - 8-
DESCRIPTION- BEHE, M. et al., "Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate", Med Oncol, (20010000), vol. 18, no. 1, pages 59 - 64-
DESCRIPTION- BOERNER et al., J. Immunol., (19910000), vol. 147, pages 86 - 95-
DESCRIPTION- BRUHNS et al., Blood., (20090000), vol. 113, no. 16, pages 3716 - 25-
DESCRIPTION- BUSHFIELD et al., Leukemia, (20140000), vol. 28, no. 11, pages 2213 - 21-
DESCRIPTION- CHAN, W.L. et al., "Lowering of trichosanthin immunogenicity by site-specific coupling to dextran", Biochem Pharmacol, (19990000), vol. 57, no. 8, pages 927 - 34-
DESCRIPTION- COLE et al., Mol. Cell. Biol., (19840000), vol. 62, pages 109 - 120-
DESCRIPTION- COLE et al., Monoclonal antibodies and Cancer Therapy, (19850000), page 77-
DESCRIPTION- COTE et al., Proc. Natl. Acad. Sci. USA, (19830000), vol. 80, pages 2026 - 2030-
DESCRIPTION- DATTA-MANNAN A. et al., Drug Metab. Dispos., (20070000), vol. 35, pages 86 - 94-
DESCRIPTION- DINARELLO, CA, Blood, (19960000), vol. 87, no. 6, pages 2095 - 147-
DESCRIPTION- DINARELLO CA, CHEST, (20000000), vol. 118, pages 503 - 508-
DESCRIPTION- DINARELLO, CA, Clin Exp Rheumatol, (20020000), vol. 20, no. 27, pages 1 - 13-
DESCRIPTION- DINARELLO et al., Nature Reviews, (20120000), vol. 11, pages 633 - 652-
DESCRIPTION- DINARELLO, Mol. Med., (20140000), vol. 20, no. 1, pages S43 - S58-
DESCRIPTION- Drug Discovery Today, (20050000), vol. 10, pages 23 - 33-
DESCRIPTION- EDELMAN et al., Proc. Natl. Acad. Sci. USA, (19690000), vol. 63, pages 78 - 85-
DESCRIPTION- Expert. Opin. Biol. Ther., (20050000), vol. 5, pages 783 - 797-
DESCRIPTION- FEBS J, (20070000), vol. 274, pages 86 - 95-
DESCRIPTION- GARLANDA et al., Immunity., (20131212), vol. 39, no. 6, pages 1003 - 18-
DESCRIPTION- GEBAUER; SKERRA, Curr Opin Chem Biol, (20090000), vol. 13, no. 3, pages 245 - 255-
DESCRIPTION- "GenBank", Database accession no. AAB84059-
DESCRIPTION- HINTON et al., J Biol Chem., (20040000), vol. 279, no. 8, pages 6213 - 6-
DESCRIPTION- HINTON et al., J. Biol. Chem., (20040000), vol. 279, no. 8, pages 6213 - 6-
DESCRIPTION- HOOGENBOOM; WINTER, J. Mol. Biol., (19910000), vol. 227, page 381-
DESCRIPTION- HUANG et al., Proc. Natl. Acad. Sci. USA., (19970000), vol. 94, no. 24, pages 12829 - 12832-
DESCRIPTION- HUANG; MILLER, Adv. Appl. Math., (19910000), vol. 12, pages 337 - 357-
DESCRIPTION- IDUSOGIE et al., J Immunol., (20000000), vol. 164, no. 8, pages 4178 - 84-
DESCRIPTION- Innovations Pharmac. Technol., (20060000), pages 27 - 30-
DESCRIPTION- JARAS et al., Proc Natl Acad Sci USA, (20100000), vol. 107, no. 37, pages 16280 - 5-
DESCRIPTION- JEFFERIS; LEFRANC, MAbs, (20090000), vol. 1, no. 4, pages 332 - 8-
DESCRIPTION- JONES et al., Nature, (19860000), vol. 321, pages 522 - 525-
DESCRIPTION- J. Pharmacol. Exp. Ther., (20060000), vol. 318, pages 803 - 809-
DESCRIPTION- KIM, D.S.; Y.J. JUNG; Y.M. KIM, "Synthesis and properties of dextran-linked ampicillin", Drug Dev Ind Pharm, (20010000), vol. 27, no. 1, pages 97 - 101-
DESCRIPTION- KOHLER et al., Nature, (19750000), vol. 256, page 4950497-
DESCRIPTION- KOZBOR et al., J. Immunol. Methods, (19850000), vol. 81, pages 31 - 42-
DESCRIPTION- KURTZHALS, P. et al., "Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo", Biochem J, (19950000), vol. 312, no. 3, pages 725 - 31, XP008005781-
DESCRIPTION- LABRIJN AF. et al., Nat Biotechnol., (20090000), vol. 27, no. 8, pages 767 - 71-
DESCRIPTION- LABRIJN et al., Nat Biotechnol., (20090000), vol. 27, no. 8, pages 767 - 71-
DESCRIPTION- LAZAR et al., PNAS, (20060000), vol. 103, no. 11, pages 4005 - 4010-
DESCRIPTION- LIDA et al., BMC Cancer, (20090000), vol. 9, page 58-
DESCRIPTION- MARKS et al., J. Mol. Biol., (19910000), vol. 222, page 581-
DESCRIPTION- MASUDA et al., Mol Immunol., (20070000), vol. 44, no. 12, pages 3122 - 31-
DESCRIPTION- Meth. Mol. Biol., (20070000), vol. 352, pages 95 - 109-
DESCRIPTION- MEZIERE et al., J. Immunol., (19970000), vol. 159, pages 3230 - 3237-
DESCRIPTION- NAKASHIMA, M. et al., "In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans", Biol Pharm Bull, (19990000), vol. 22, no. 7, pages 756 - 61-
DESCRIPTION- Nat. Biotechnol., (20040000), vol. 22, pages 575 - 582-
DESCRIPTION- Nat. Biotechnol., (20050000), vol. 23, pages 1556 - 1561-
DESCRIPTION- "NCBI", Database accession no. NP_002173.1-
DESCRIPTION- NYGREN, FEBS J, (20080000), vol. 275, pages 2668 - 2676-
DESCRIPTION- OKAZAKI et al., J Mol Biol., (20040000), vol. 336, no. 5, pages 1239 - 49-
DESCRIPTION- ORLANDI. et al., Proc. Natl. Acad. Sci. U.S.A., (19890000), vol. 86, pages 3833 - 3837-
DESCRIPTION- PEIPP et al., Blood, (20080000), vol. 112, no. 6, pages 2390 - 9-
DESCRIPTION- PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596-
DESCRIPTION- PULE et al., Cytotherapy, (20030000), vol. 5, no. 3, pages 211 - 26-
DESCRIPTION- REICHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327-
DESCRIPTION- RICHARDS et al., Mol Cancer Ther., (20080000), vol. 7, no. 8, pages 2517 - 27-
DESCRIPTION- RICHARDS et al., Mol Cancer There., (20080000), vol. 7, no. 8, pages 2517 - 27-
DESCRIPTION- RIDKER et al., Am Heart Journal, (20110000), vol. 162, no. 4, pages 597 - 605-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329-
DESCRIPTION- RYAN et al., Mol. Cancer Ther., (20070000), vol. 6, pages 3009 - 3018-
DESCRIPTION- SHIELDS et al., J Biol Chem., (20010000), vol. 276, no. 9, pages 6591 - 604-
DESCRIPTION- SHIELDS RL. et al., J Biol Chem., (20010000), vol. 276, no. 9, pages 6591 - 604-
DESCRIPTION- STEURER et al., J Immunol., (19950000), vol. 155, no. 3, pages 1165 - 74-
DESCRIPTION- STEURERW. et al., J Immunol., (19950000), vol. 155, no. 3, pages 1165 - 74-
DESCRIPTION- STROHL, Curr Opin Biotechnol, (20090000), vol. 20, no. 6, pages 685 - 91-
DESCRIPTION- SYED, S.; K.E. KELLY; W.P. SHEFFIELD, "Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin", Thromb Res, (19960000), vol. 84, no. 6, pages 419 - 29-
DESCRIPTION- THOMPSON et al., Nucl. Acid Res., (19940000), vol. 22, pages 4673 - 4680-
DESCRIPTION- THURSELL et al., Biochem. Biophys. Res. Comm., (19830000), vol. 111, page 166-
DESCRIPTION- Trends. Biotechnol., (20050000), vol. 23, pages 514 - 522-
DESCRIPTION- "UniProtKB/Swiss-Prot", Database accession no. Q9NPH3-
DESCRIPTION- "UniProtKB/Swiss-Prot", Database accession no. Q9NPH3-1-
DESCRIPTION- VACCARO et al., Nat Biotechnol., (20050000), vol. 23, no. 10, pages 1283 - 8-
DESCRIPTION- VACCARO et al., Nat. Biotechnol., (20050000), vol. 23, no. 10, pages 1283 - 8-
DESCRIPTION- VEBER et al., Proc. Natl. Acad. Sci. USA, (19780000), vol. 75, page 2636-
DESCRIPTION- VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 15361-
DESCRIPTION- VIGNE et al., Blood, (20120000), vol. 120, no. 17, pages 3478 - 87-
DESCRIPTION- VISVADER; LINDEMAN, Nat Rev Cancer, (20080000), vol. 8, pages 755 - 768-
DESCRIPTION- WANG et al., Nature Immunology, (20100000), vol. 11, pages 905 - 912-
DESCRIPTION- WINTER et al., Nature, (19910000), vol. 349, pages 293 - 299-
DESCRIPTION- WULBRAND, U. et al., "A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes", Cancer, (20020000), vol. 94, no. 4, pages 1293 - 7-
DESCRIPTION- YAMANE-OHNUKI; SATOH, MAbs, (20090000), vol. 1, no. 3, pages 230 - 26-
DESCRIPTION- ZALEVSKY et al., Nat. Biotechnology, (20100000), vol. 28, no. 2, pages 157 - 159-
DESCRIPTION- HAMILTON-WESSLER, M. et al., "Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin", Diabetologia, (19990000), vol. 42, no. 10, doi:doi:10.1007/s001250051301, pages 1254 - 63, XP002378530
DESCRIPTION- OSBORN, B.L. et al., "Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys", Eur J Pharmacol, (20020000), vol. 456, no. 1-3, doi:doi:10.1016/S0014-2999(02)02644-4, pages 149 - 58, XP002339364
DESCRIPTION- GOLDENBERG, M.M., "Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis", Clin Ther, (19990000), no. 1, doi:doi:10.1016/S0149-2918(00)88269-7, pages 75 - 87, XP055069063
DESCRIPTION- YURA, H. et al., "Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate", J Control Release, (19990000), vol. 57, no. 1, doi:doi:10.1016/S0168-3659(98)00150-3, pages 87 - 99, XP004155643
DESCRIPTION- SATO, H., "Enzymatic procedure for site-specific pegylation of proteins", Adv Drug Deliv Rev, (20020000), vol. 54, no. 4, doi:doi:10.1016/S0169-409X(02)00024-8, pages 487 - 504, XP002390064
DESCRIPTION- CHAPMAN, A.P., "PEGylated antibodies and antibody fragments for improved therapy: a review", Adv Drug Deliv Rev, (20020000), vol. 54, no. 4, doi:doi:10.1016/S0169-409X(02)00026-1, pages 531 - 45, XP001199533
DESCRIPTION- WANG, Y.S. et al., "Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications", Adv Drug Deliv Rev, (20020000), vol. 54, no. 4, doi:doi:10.1016/S0169-409X(02)00027-3, pages 547 - 70, XP002989691
DESCRIPTION- WANG, Y.S. et al., "tructural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications", Adv Drug Deliv Rev, (20020000), vol. 54, no. 4, doi:doi:10.1016/S0169-409X(02)00027-3, pages 547 - 70, XP002989691
DESCRIPTION- VERONESE, F.M.; J.M. HARRIS, "Introduction and overview of peptide and protein pegylation", Adv Drug Deliv Rev, (20020000), vol. 54, no. 4, doi:doi:10.1016/S0169-409X(02)00029-7, pages 453 - 6, XP002464348
DESCRIPTION- BOWEN, S. et al., "Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein", Exp Hematol, (19990000), vol. 27, no. 3, doi:doi:10.1016/S0301-472X(98)00051-4, pages 425 - 32, XP008053962
DESCRIPTION- MOLINEUX, G., "Pegylation: engineering improved pharmaceuticals for enhanced therapy", Cancer Treat Rev, (20020000), vol. 28, no. A, doi:doi:10.1016/S0305-7372(02)80004-4, pages 13 - 6, XP026518515
DESCRIPTION- VERONESE, F.M.; G. PASUT, "PEGylation, successful approach to drug delivery", Drug Discov Today, (20050000), vol. 10, no. 21, doi:doi:10.1016/S1359-6446(05)03575-0, pages 1451 - 8, XP005124583
DESCRIPTION- BAUDYS, M. et al., "Extending insulin action in vivo by conjugation to carboxymethyl dextran", Bioconjug Chem, (19980000), vol. 9, no. 2, doi:doi:10.1021/bc970180a, pages 176 - 83, XP002363506
DESCRIPTION- CHAPMAN, A.P. et al., "Therapeutic antibody fragments with prolonged in vivo half-lives", Nat Biotechnol, (19990000), vol. 17, no. 8, doi:doi:10.1038/11717, pages 780 - 3, XP001199462
DESCRIPTION- ELLIOTT, S. et al., "Enhancement of therapeutic protein in vivo activities through glycoengineering", Nat Biotechnol, (20030000), vol. 21, no. 4, doi:doi:10.1038/nbt799, pages 414 - 21, XP002354911
DESCRIPTION- OSBORN, B.L. et al., "Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomoigus monkeys", J Pharmacol Exp Ther, (20020000), vol. 303, no. 2, doi:doi:10.1124/jpet.102.037002, pages 540 - 8, XP003006693
DESCRIPTION- OSBORN, B.L. et al., "Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys", J Pharmacol Exp Ther, (20020000), vol. 303, no. 2, doi:doi:10.1124/jpet.102.037002, pages 540 - 8, XP003006693
OPPOSITION- 2022-05-26 Cantargia AB Press Release 1-
OPPOSITION- 2022-05-26 Cantargia AB Press Release 2-
OPPOSITION- 2022-05-26 Cantargia AB Press Release 3-
OPPOSITION- Anonymous, "Human IL -1 RAcP/ IL -1 R3 Antibody: Monoclonal Mouse IgG1 Clone # 89412 Catalog Number: MAB676", R&D systems, (20180702), pages 1 - 2, XP055873727-
OPPOSITION- Askmyr, Mana et al., "Selective killing of candidate AML stemcells by antibody targeting of IL1 RAP" Blood, Vol. 121,02 May 2013-
OPPOSITION- Barreyro, Laura et al., "Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS" Blood . Vol. 120. No. 6. 09 August 2012-
OPPOSITION- By-Passing Immunization. Building High Affinity HumanAntibodies by Chain Shufffmg. Marks, J , Griffiths, A .Malmqvist, M. et al. Nat Biotechnol 10, 779-783 (1992)http://doi.org/10.1038/nbt0792-779-
OPPOSITION- Data Sheet: Human IL-1 RAcP/IL-1 R3 Antibody: Monoclonal Mouse lgG1 Clone # 89412 Catalog Number: MAB676 R&D Systems. 2/7/18-
OPPOSITION- High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1. Opali-ski • etal., Int J Mol Sci. 2018 May;19(5): 1435-
OPPOSITION- Improving antibody affinity by mimicking somatic hypermutation in vitro. Chowdhury P„ Pastan, I. Nat Biotechnol 17, 568-572(1999)-
OPPOSITION- Isolation of Picomolar Affinity Anti.-c-erbB-2 Single Cham Fv by Molecular Evolution of the Complementarity Determining Regions in the Centre of the Antibody Bidning Site. Schier et al.Journal of Molecular Biology, Volume 263, Issue 4, 1996,Pages 551-567 https//doi.orq/10 1006/imbi 1996.0598-
OPPOSITION- Liliom et al., 1991, J Immunol Methods, Sep 20;143(1 ):119-25-
OPPOSITION- Lingel, Andreas et al, "Structure of IL-33 and Its Inter action with the ST2 and IL-1RAcP Receptors-Insight into eterotnmeric IL-1 Signaling Complexes" Structure, Vol. 17, 14 October 2009-
OPPOSITION- Liu, Xi et al., "Structural insights into the interaction of IL-33 with its receptors" Proceedings of the National Academy of Sciences of the United States of America. Vol. 110, No. 37,10 September 2013-
OPPOSITION- Luchini A., Espina V., Liotta L. A., "Protein painting reveals solvent-excluded drugtargets hidden within native protein-proteininterfaces ", Nature Communications, (20140722), vol. 5, no. 4413, pages 1 - 12, XP055883512-
OPPOSITION- Product Datasheet - Human IL-1 RacP/IL-1 R3 Antibody (R&D System)-
OPPOSITION- Selective killing of candidate AML stem cells by antibody targeting of IL1 RAP. Supplemental Data, Askmyr M. et al.Blood 2013-
OPPOSITION- Sparks and Ballow, 1983, Diagnostic Immunology, 1(4):269-275-
OPPOSITION- Thomas, Christoph et al., "Structure of the activating IL-1 receptor signaling complex" Nature Structural & Molecular Biology , Vol. 19, No. 4, April 2012-
OPPOSITION- Towne et al. The Journal of Biological Chemistry. Vol. 279, No.14. Issue of April 2. pp. 13677-13688. 2004-
OPPOSITION- Wang, Dongli et al., "Structural insights into the assembly and activation of IL-1 Beta with its receptors" Nature Immunology ,Vol. 11, No. 10, October 2010-
OPPOSITION- Yoon, "Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein.", The Journal of Immunology, (19980401), vol. 160, no. 7, pages 3170 - 3179, XP055191790-
OPPOSITION- Yoon, Do-Young et al, "Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1 Beta Activity But Not Binding: Regulation of IL-1 Responses Is Via Type I Receptor, Not the Receptor Accessory Protein" The Journal of Immunology , Vol. 160, No. 7, 01 April 1998-
OPPOSITION- YOON et al., "Antibodies to Domains II and III of the IL -1 Receptor Accessory Protein Inhibit IL -1beta Activity But Not Binding: Regulation of IL -1 Responses Is Via Type I Receptor, Not the Receptor Accessory Protein", J. Immunol., (19980401), vol. 160, no. 7, pages 3170 - 3179, XP055191790-
OPPOSITION- LINGEL et al., "Structure of IL -33 and Its Interaction with the ST2 and IL - 1RAcP Receptors-Insight into Heterotrimeric IL -1 Signaling Complexes", Structure, (20091014), vol. 17, doi:10.1016/j.str.2009.08.009, pages 1398 - 1410, XP026932729
OPPOSITION- Wang Dongli et al, "Structural insights into the assembly and activation of IL-1β with its receptors", Nature Immulogy, Nature Publishing Group US, New York, New York , (20101001), vol. 11, no. 10, doi:10.1038/ni.1925, ISSN 1529-2908, pages 905 - 911, XP055873733
OPPOSITION- Wang Dongli, Zhang Senyan, Li Liang, Liu Xi, Mei Kunrong, Wang Xinquan, "Structural insights into the assembly and activation of IL-1β with its receptors", Nature Immulogy, Nature Publishing Group US, New York, New York , (20101001), vol. 11, no. 10, doi:10.1038/ni.1925, ISSN 1529-2908, pages 905 - 911, XP055873733
OPPOSITION- Thomas Christoph, Bazan J Fernando, Garcia K Christopher, "Structure of the activating IL-1 receptor signaling complex", NAT. STRUCT. MOL. BIOL., Nature Publishing Group US, New York, New York , (20120401), vol. 19, no. 4, doi:10.1038/nsmb.2260, ISSN 1545-9993, pages 455 - 457, XP055873738
OPPOSITION- Ali Shafaqat; Huber Michael; Kollewe Christian; Bischoff Stephan C; Falk Werner; Martin Michael U, "IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells.", PNAS, Proceedings of the National Academy of Sciences, National Academy of Sciences, US, US , (20071120), vol. 104, no. 47, doi:10.1073/pnas.0705939104, ISSN 1091-6490, pages 18660 - 18665, XP009169532
OPPOSITION- Liu X. et al, "Structural insights into the interaction of IL-33 with its receptors", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20130910), vol. 110, no. 37, doi:10.1073/pnas.1308651110, ISSN 0027-8424, pages 14918 - 14923, XP055871966
OPPOSITION- TOWNE JENNIFER E ET AL, "Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20040402), vol. 279, no. 14, doi:10.1074/jbc.M400117200, ISSN 0021-9258, pages 13677 - 13688, XP002472229
OPPOSITION- Barreyro Laura, Et Al, "Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS", Blood, American Society of Hematology, US, US , (20120809), vol. 120, no. 6, doi:10.1182/blood-2012-01-404699, ISSN 0006-4971, pages 1290 - 1298, XP055873730
OPPOSITION- ASKMYR et al., "Selective killing of candidate AML stem cells by antibody targeting of IL 1RAP", Blood, vol. 121, no. 18, doi:10.1182/blood-2012-09-458935, pages 3709 - 3713, XP055191654
OPPOSITION- Ross Stewart;Scott A Hammond;Michael Oberst;Robert W Wilkinson, "The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB , (20140819), vol. 2, no. 1, doi:10.1186/s40425-014-0029-x, ISSN 2051-1426, page 29, XP021193931
SEARCH- YOON, "Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein.", THE JOURNAL OF IMMUNOLOGY, (19980401), vol. 160, no. 7, pages 3170 - 3179, XP055191790 [X] 1-15 * page 3171, line l, paragraph l - line 1, paragraph r * * page 3173 * * paragraph [results] *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents